Comparison of Intra-Articular Injections of Plasma Rich in Growth Factors (PRGF-Endoret) Versus Durolane Hyaluronic Acid in the Treatment of Patients With Symptomatic Osteoarthritis: A Randomized Controlled Trial


      The purpose of this study was to compare the efficacy and safety in a randomized, clinical trial of 3 injections of PRGF-Endoret (BTI Biotechnology Institute, Vitoria, Spain) versus one single intra-articular injection of Durolane hyaluronic acid (HA) (Q-MED AB, Uppsala, Sweden) as a treatment for reducing symptoms in patients with knee osteoarthritis (OA).


      Ninety-six patients with symptomatic knee OA were randomly assigned to receive PRGF-Endoret (3 injections on a weekly basis) or one infiltration with Durolane HA. The primary outcome measures were a 30% decrease and a 50% decrease in the summed score for the pain, physical function, and stiffness subscales of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Lequesne scores from baseline to weeks 24 and 48. The percentage of OMERACT-OARSI (Outcome Measures for Rheumatology Committee and Osteoarthritis Research Society International Standing Committee for Clinical Trials Response Criteria Initiative) responders was also documented. As secondary outcomes, pain, stiffness, and physical function by use of the WOMAC and the Lequesne score were considered and overall safety of the injection themselves.


      The mean age of the patients was 63.6 years. Treatment with PRGF-Endoret was significantly more efficient than treatment with Durolane HA in reducing knee pain and stiffness and improving physical function in patients with knee OA. The rate of response to PRGF-Endoret was significantly higher than the rate of response to HA for all the scores including pain, stiffness, and physical function on the WOMAC, Lequesne index, and OMERACT-OARSI responders at 24 and 48 weeks. Adverse events were mild and evenly distributed between the groups.


      Our findings show that PRGF-Endoret is safe and significantly superior to Durolane HA in primary and secondary efficacy analysis both at 24 and 48 weeks; provides a significant clinical improvement, reducing patients' pain and improving joint stiffness and physical function with respect to basal levels in patients with knee OA; and should be considered in the treatment of patients with knee OA.

      Level of Evidence

      Level I, multicenter randomized controlled clinical trial.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Arthroscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kosorok M.R.
        • Omenn G.S.
        • Diehr P.
        • Koepsell T.D.
        • Patrick D.L.
        Restricted activity days among older adults.
        Am J Public Health. 1992; 82: 1263-1267
        • Guccione A.A.
        • Felson D.T.
        • Anderson J.J.
        • et al.
        The effects of specific medical conditions on the functional limitation of elders in the Framingham Study.
        Am J Public Health. 1994; 84: 351-358
        • Bijlsma J.W.J.
        • Berenbaum F.
        • Lafeber F.P.J.G.
        Osteoarthritis: An update with relevance for clinical practice.
        Lancet. 2011; 377: 2115-2126
        • Centers for Disease Control and Prevention (CDC)
        Prevalence of disabilities and associated health conditions among adults.
        MMWR Morb Mortal Wkly Rep. 2001; 50: 120-125
        • Zhang W.
        • Moskowitz R.W.
        • Nuki G.
        • et al.
        OARSI recommendations for the management of hip and knee osteoarthritis, part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence.
        Osteoarthritis Cartilage. 2007; 15: 981-1000
        • Ayral X.
        • Pickering E.H.
        • Woodworth T.G.
        • Mackillop N.
        • Dougados M.
        Synovitis: A potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis—Results of a 1 year longitudinal arthroscopic study in 422 patients.
        Osteoarthritis Cartilage. 2005; 13: 361-367
        • Heinegard D.
        • Saxne T.
        The role of the cartilage matrix in osteoarthritis.
        Nat Rev Rheumatol. 2011; 7: 50-56
        • Anitua E.
        • Sánchez M.
        • Orive G.
        • Andía I.
        The potential impact of the preparation rich in growth factors (PRGF) in different medical fields.
        Biomaterials. 2007; 28: 4551-4560
        • Anitua E.
        • Sánchez M.
        • Orive G.
        Potential of endogenous regenerative technology for in situ regenerative medicine.
        Adv Drug Deliv Rev. 2010; 62: 741-752
        • Sánchez M.
        • Anitua E.
        • Azofra J.
        • Aguirre J.J.
        • Andia I.
        Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: A retrospective cohort study.
        Clin Exp Rheumatol. 2008; 26: 910-913
        • Filardo G.
        • Kon E.
        • Pereira Ruiz M.T.
        • et al.
        Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: Single- versus double-spinning approach.
        Knee Surg Sports Traumatol Arthrosc. 2012; 20: 2082-2091
        • Sánchez M.
        • Fiz N.
        • Azofra J.
        • et al.
        A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis.
        Arthroscopy. 2012; 28: 1070-1078
        • Altman R.D.
        • Akermark C.
        • Beaulieu A.D.
        • Schnitzer T.
        • Durolane International Study Group
        Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee.
        Osteoarthritis Cartilage. 2004; 12: 642-649
      1. Leighton RK, Arden N. A randomized blinded trial comparing one HA injection to corticosteroid for knee osteoarthritis pain. Presented at the American Academy of Orthopaedic Surgeons Annual Meeting; New Orleans, LA; March 2010. PN 640: 583.

        • Samper Bernal D.
        • Jiménez Capel Y.
        • Hinojosa Zaguirre M.
        • et al.
        Efectividad y seguridad de la viscosuplementación con dosis única de ácido Hialurónico estabilizado de origen no animal (NASHA) para el tratamiento del dolor secundario a gonartrosis.
        Rev Soc Esp Dolor. 2012; 19: 259-263
        • Altman R.
        • Asch E.
        • Bolch D.
        • et al.
        Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee.
        Arthritis Rheum. 1986; 29: 1039-1049
        • Bellamy N.
        • Buchanan W.W.
        • Goldsmith C.H.
        Validation study of WOMAC: A health status instrument for measuring clinically, important patient, relevant outcomes following total hip or knee arthroplasty in an osteoarthritis.
        J Orthop Rheumatol. 1988; 1: 95-108
        • Pham T.
        • van der Heijde D.
        • Altman R.D.
        • et al.
        OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.
        Osteoarthritis Cartilage. 2004; 12: 389-399
        • Lequesne M.G.
        • Mery C.
        • Samson M.
        • et al.
        Indexes of severity for osteoarthritis of the hip and knee. Validation-value in comparison with other assessment tests.
        Scand J Rheumatol Suppl. 1987; 65: 85-89
        • Wang-Saegusa A.
        • Cugat R.
        • Ares O.
        • Seijas R.
        • Cuscó X.
        • García-Balletbó M.
        Infiltration of plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and quality of life.
        Arch Orthop Trauma Surg. 2011; 131: 311-317
        • Rowbotham M.C.
        What is a “clinically meaningful” reduction in pain?.
        Pain. 2001; 94: 131-132
        • Salaffi F.
        • Stancati A.
        • Silvestri C.A.
        • Ciapetti A.
        • Grassi W.
        Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale.
        Eur J Pain. 2004; 8: 283-291
        • Yoshioka T.
        • Kanamori A.
        • Washio T.
        • et al.
        The effects of plasma rich in growth factors (PRGF-Endoret) on healing of medial collateral ligament of the knee.
        Knee Surg Sports Traumatol Arthrosc. 2013; 21: 1763-1769
        • Filardo G.
        • Kon E.
        • Di Martino A.
        • et al.
        Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: Study design and preliminary results of a randomized controlled trial.
        BMC Musculoskelet Disord. 2012; 13: 229
        • Kon E.
        • Mandelbaum B.
        • Buda R.
        • et al.
        Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: From early degeneration to osteoarthritis.
        Arthroscopy. 2011; 27: 1490-1501
        • Schmidt M.B.
        • Chen E.H.
        • Lynch S.E.
        A review of the effects of insulin-like growth factor and platelet derived growth factor on in vivo cartilage healing and repair.
        Osteoarthritis Cartilage. 2006; 14: 403-412
        • Martin J.A.
        • Buckwalter J.A.
        The role of chondrocyte-matrix interactions in maintaining and repairing articular cartilage.
        Biorheology. 2000; 37: 129-140
        • Frazer A.
        • Bunning R.A.
        • Thavarajah M.
        • Seid J.M.
        • Russell R.G.
        Studies on type II collagen and aggrecan production in human articular chondrocytes in vitro and effects of transforming growth factor-beta and interleukin-1beta.
        Osteoarthritis Cartilage. 1994; 2: 235-245
        • van Buul G.M.
        • Koevoet W.L.
        • Kops N.
        • et al.
        Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes.
        Am J Sports Med. 2011; 39: 2362-2370
        • Pujol J.P.
        • Chadjichristos C.
        • Legendre F.
        • et al.
        Interleukin-1 and transforming growth factor-beta 1 as crucial factors in osteoarthritic cartilage metabolism.
        Connect Tissue Res. 2008; 49: 293-297